Crunching the numbers. Responsibly.
Background Remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, demonstrated significant improvements in disease activity over placebo in the 24-week phase 3 REMIX studies in patients with chronic spontaneous urticaria (CSU) remaining symptomatic despite second-generation H 1 -antihistamines. Objective We sought to evaluate the long-term efficacy and safety of remibrutinib in patients with CSU. Methods REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were two randomized placebo-controlled studies evaluating the efficacy, safety, and tolerability of remibrutinib in patients with CSU. Patients were randomized 2:1 to receive oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks). The primary end point was change from baseline in weekly Urticaria Activity Score at week 12. Results A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive remibrutinib (n = 313 and 300, respectively) or placebo (n = 157 and 155, respectively). At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score (mean [95% confidence interval], REMIX-1: −23.22 [−24.78, −21.66]; REMIX-2: −22.98 [−24.51, −21.44]), with similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning). Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis. Conclusion Remibrutinib showed sustained efficacy and a consistent, favorable long-term safety profile in patients with CSU remaining symptomatic despite second-generation H 1 -antihistamines.
At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score
consistent results across two studies, limited by open-label observed-data follow-up after week 24
similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning)
post hoc open-label transition results on a subjective outcome without a continuing placebo comparator
Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis
systematic safety surveillance and exposure-adjusted event rates across the reported treatment periods
Remibrutinib showed sustained efficacy and a consistent, favorable long-term safety profile in patients with CSU remaining symptomatic despite second-generation H1-antihistamines
substantial symptom and safety evidence, with long-term efficacy limited by uncontrolled observed-data follow-up
Derived from the full evaluation — not a separate score.
Strengths
The study extends the prior 24-week analysis to 52 weeks in two phase 3 cohorts, directly addressing durability and longer safety exposure in a chronic condition.
↳ Introduction, final paragraph; Results, Efficacy and Safety
Adverse events, serious events, discontinuations, infections, laboratory findings, and petechiae are reported with exposure-adjusted rates and clinically relevant detail.
↳ Methods, Safety; Results, Safety; Table I
The target population is adults whose CSU remains symptomatic despite second-generation antihistamines, with remibrutinib positioned as an oral add-on treatment option.
↳ Introduction; Discussion; Clinical implication
Limitations
After week 24, all continuing patients received remibrutinib, while efficacy remained based on patient-reported UAS7. This limits causal interpretation of maintained and transition-cohort responses.
↳ Methods, Study design and Study assessments; Results, Efficacy
Week-52 efficacy is summarized using observed data, with no reported imputation or sensitivity analysis to assess whether discontinuation or missing outcomes altered the estimates.
↳ Methods, Statistical analyses; Figures 2–5; Results, Disposition
The open-label design is disclosed, but the Discussion and Conclusion do not explicitly explain how the missing concurrent comparator reduces certainty in the sustained-efficacy interpretation.
↳ Methods, Study design; Discussion and Conclusion
The report makes a clear incremental contribution by extending two pivotal studies from 24 to 52 weeks and documenting accumulated safety exposure in Table I. Its safety analysis is systematic, while exploratory and post hoc efficacy analyses are generally labeled transparently. The principal methodological constraint is that all patients received active treatment after week 24, leaving long-term patient-reported efficacy without a concurrent comparator. Confidence is further moderated by the use of observed-data summaries without a reported missing-data sensitivity analysis and by the limited discussion of these interpretive constraints.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.4
Confidence mediumThe report meaningfully extends the prior 24-week trial analysis by adding 52-week symptom and accumulated safety observations from two phase 3 studies. Its contribution remains incremental because the principal randomized efficacy comparison was previously reported and no placebo comparator continued after week 24.
“long-term, 52-week data from the phase 3 REMIX studies”
The studies use defined analysis sets, registered endpoints, systematic adverse-event surveillance, and exposure-adjusted safety rates. Long-term efficacy relies on an open-label period using patient-reported UAS7 and observed data without a reported missing-data sensitivity analysis.
“based on a descriptive summary of observed data”
The manuscript consistently separates the original placebo-controlled period, the open-label transition, and exploratory or post hoc analyses. The abstract and conclusion describe sustained efficacy more firmly than warranted by an uncontrolled extension, although the abstract also discloses the open-label design.
“followed by a 28-week open-label treatment period”
The introduction situates the study against CSU guidelines, persistent symptoms, current escalation options, and the prior 24-week REMIX report. The Discussion does not explicitly trace the lack of a post-week-24 comparator or observed-data analysis into reduced certainty for the 52-week efficacy conclusion.
“Important questions about treatment discontinuation, symptom recurrence, and monotherapy are being addressed”
Caveats4 of 4 checks
Reported sample sizes, efficacy estimates, and safety denominators are internally compatible. Week-52 efficacy nevertheless relies on descriptive observed-data summaries without imputation or sensitivity analysis, leaving noted uncertainty about the influence of missing outcomes.
Ethics approval, written informed consent, prospective trial registration, sponsor involvement, funding, and conflicts of interest are declared. No location-referenced conduct concern meeting the noted or concern threshold was established.
Flags: 3 declared / 5 total
28 of 32 checkable references verified
32 references in manuscript
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The evidence comes from two completed phase 3 studies in the intended clinical population, including 52-week safety exposure. Readiness is advanced but not equivalent to real-world implementation, and the long-term efficacy period lacks a concurrent comparator.
“two randomized placebo-controlled studies”
AI-generated, human-governed. Something look off? Contact us to request a review.